Entrada Therapeutics

$7.99 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Entrada Therapeutics

Entrada Therapeutics, Inc is an intracellular therapeutics company. The Company is engaged in offering Endosomal Escape Vehicle (EEV) therapeutics as a new class of medicines for the patients. EEV therapeutics are comprised of small cyclic peptides that are chemically conjugated to a range of specific and active biological therapeutics. Its EEV therapeutics are designed to engage intracellular targets that have long been considered inaccessible and undruggable. It builds a development portfolio of EEV therapeutic candidates designed to enable the intracellular delivery of therapeutics in various organs and tissues with an improved therapeutic index. Its ENTR-501, an intracellular thymidine phosphorylase (TP) enzyme replacement therapy (ERT), program is in development for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

Stock Analysis

last close $8.01
1-mo return -47.8%
3-mo return -
avg daily vol. 105.28T
52-week high 36.85
52-week low 7.89
market cap. $258M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $--
inst own. 50.9%

Subscribe now for daily local and international financial news